Lakefront Biotherapeutics: stock overview

LKFTNASDAQHealthcare · Pharmaceutical Preparations

Price

$33.31

November 20, 2026Market cap $2.2B

What Ploutos Investor adds for Lakefront Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Lakefront Biotherapeutics had revenue of $1.3B in the fiscal year to December 31, 2025 and net income of $377M, a net margin of 28.8%. Revenue grew by 18.4% a year on average over the last 5 years. At $33.31 the shares trade at a P/E of 5.8, against a median of 11.5 over the last 3 fiscal years. It holds more cash than debt, by $95M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$2.2B
65.90M shares
P/E
5.8
Today5.8
Median11.5
Revenue, fiscal year
$1.3B
+18.4% a year over 5 years
Net margin
28.8%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+115.4% a year over 2 years

  • 202520-F
    Revenue$1.3B
  • 202420-F
    Revenue$285M
  • 202320-F
    Revenue$265M

Fiscal years in figures

LKFT's revenue, profit, cash flow and dividend with each year-end price, from 2015 to 2022, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $2.2B
$2.2B
Enterprise value 
$2.1B
P/E 3-year median: 11.4
5.8
EV / EBIT 
6.1
EV / Revenue 
1.6
P/B 3-year median: 0.6
0.6
FCF yield 3-year median: -17.5%
–
Earnings yield 3-year median: 8.7%
17.2%

Profitability

Gross margin 
97.3%
Operating margin 
26.5%
Net margin 3-year median: 28.9%
28.8%
ROIC 
7.2%
ROIC, 5-year average 
-1.9%
ROE, fiscal year 
9.9%

Growth

Revenue, yearly change 
+303.5%
EPS, yearly change 
+334.8%
FCF, yearly change 
–
Revenue, average a year 
+18.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$103M
Total debt 
$8.1M
Net cash 
$95M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
0.0%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Lakefront Biotherapeutics NV
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Latest annual report
December 31, 2025
Reporting currency
EUR
Shares
65.90M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Lakefront Biotherapeutics's filings show?

These are Lakefront Biotherapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LKFT

Didn't find what you were looking for?

Ask us
What is LKFT's market cap?

Lakefront Biotherapeutics's market cap is $2.2B, at a price of $33.31 on November 20, 2026 and 65.90M shares.

What is LKFT's P/E?

LKFT's P/E is 5.8, on earnings per share of $5.72 in the fiscal year to December 31, 2025. The median over the last 3 fiscal years was 11.5.

How much revenue does LKFT have?

Lakefront Biotherapeutics had revenue of $1.3B in the fiscal year to December 31, 2025. Over the last 5 years it changed by +18.4% a year on average.

Does LKFT pay a dividend?

No. Lakefront Biotherapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Lakefront Biotherapeutics's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.